Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Single Dose Tolvaptan 7.5mg in Healthy Males
NCT07166783Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Jun 2011
- Primary completion
- Jul 2011
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tolvaptan in hyponatremia and autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Holdings. Primary endpoint: Tolvaptan Pharmacokinetic Parameters at 144 hours. Started Jun 2011; status: completed.
02
Drugs
tolvaptan
03
Conditions
hyponatremiaautosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07166783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166783.